LPA
Apolipoprotein
As of the edition of 20 October 2026, LPA (apolipoprotein, UniProt P08519) has 3 drugs tested at it and 4 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P08519
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Solved structures
- 16
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive; Nervous system
- Registered trials of its drugs
- 25
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Status not established | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Pelacarsen | Active | Phase 3 | none listed |
| Olpasiran | Active | Phase 3 | none listed |
| Zerlasiran | Status not established | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 3 |
| Undetermined | 1 |
| Total on the list | 4 |